Lilly raises outlook for third time this year as Zepbound sales soar
The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.
Read the full story at MarketWatch TopOpen in the live monitor
The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.
Read the full story at MarketWatch TopOpen in the live monitor
No group discusses this yet. Start a discussion group and attach this story.